NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Strategic Crossroads | Neo Performance Materials faces pivotal decisions as it navigates market challenges and explores strategic alternatives, potentially reshaping its future in advanced materials |
European Expansion | Delve into Neo's new agreement with a major European automotive supplier, signaling growth potential in the electric vehicle and green technology sectors |
Market Dynamics | Explore the complexities of the rare earths market, including geopolitical factors, supply chain challenges, and Neo's positioning amidst industry volatility |
Financial Outlook | Analysts project positive earnings for Neo, with Stifel setting a C$13.00 price target. The company's strategic review remains the primary value drive |
Metrics to compare | NEO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNEOPeersSector | |
---|---|---|---|---|
P/E Ratio | −16.5x | −1.1x | −0.5x | |
PEG Ratio | −1.45 | −0.04 | 0.00 | |
Price/Book | 1.4x | 1.3x | 2.6x | |
Price / LTM Sales | 2.0x | 1.2x | 2.9x | |
Upside (Analyst Target) | 79.6% | 23.6% | 58.9% | |
Fair Value Upside | Unlock | 6.1% | 8.0% | Unlock |